[
  {
    "ts": null,
    "headline": "Kymera Therapeutics Q4 Earnings Call Highlights",
    "summary": "Kymera Therapeutics (NASDAQ:KYMR) used its fourth-quarter 2025 update call to highlight what management described as a “breakout year” driven by clinical progress for its oral STAT6 degrader KT-621, the launch of a new IRF5 degrader program with KT-579 entering the clinic, and strengthened finances",
    "url": "https://finnhub.io/api/news?id=6aeaaa303f1be68fe8e189db89c65ade2a91c8f141761f1a9b7e40112e32cce8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772143415,
      "headline": "Kymera Therapeutics Q4 Earnings Call Highlights",
      "id": 139240961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics (NASDAQ:KYMR) used its fourth-quarter 2025 update call to highlight what management described as a “breakout year” driven by clinical progress for its oral STAT6 degrader KT-621, the launch of a new IRF5 degrader program with KT-579 entering the clinic, and strengthened finances",
      "url": "https://finnhub.io/api/news?id=6aeaaa303f1be68fe8e189db89c65ade2a91c8f141761f1a9b7e40112e32cce8"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...",
    "summary": "Kymera Therapeutics Inc (KYMR) reports robust financial health and significant progress in clinical trials, setting a strong foundation for future growth.",
    "url": "https://finnhub.io/api/news?id=d0dccc57816906e8aa10bf780f1f481ff699ffef4dc7fd86e2267693aa2b87bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772140086,
      "headline": "Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...",
      "id": 139239900,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics Inc (KYMR) reports robust financial health and significant progress in clinical trials, setting a strong foundation for future growth.",
      "url": "https://finnhub.io/api/news?id=d0dccc57816906e8aa10bf780f1f481ff699ffef4dc7fd86e2267693aa2b87bd"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=91d1cc941199a8c2ec66baa7da89c796b4848119071aa56e9d11a495ff5a38f2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772123700,
      "headline": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
      "id": 139252708,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=91d1cc941199a8c2ec66baa7da89c796b4848119071aa56e9d11a495ff5a38f2"
    }
  },
  {
    "ts": null,
    "headline": "Novartis, Genentech file suit alleging illegal importation of prescription drug",
    "summary": "Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.",
    "url": "https://finnhub.io/api/news?id=1ff2a290d79dde29bdb7dee6a3bf3713531c12ebafcc6f0d7d2d246a2c5dec42",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772120688,
      "headline": "Novartis, Genentech file suit alleging illegal importation of prescription drug",
      "id": 139252762,
      "image": "https://image.cnbcfm.com/api/v1/image/108217126-1761567809501-gettyimages-2233897287-AFP_73VA2G3.jpeg?v=1772141306&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.",
      "url": "https://finnhub.io/api/news?id=1ff2a290d79dde29bdb7dee6a3bf3713531c12ebafcc6f0d7d2d246a2c5dec42"
    }
  }
]